English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Atopic patients with severe asthma frequently have poorly controlled disease despite intensive treatment. These patients are frequently treated with oral corticosteroids which can results in serious sideeffects. Anti-IgE antibody had been used in severe persistent allergic asthma. However, its long-term efficacy in patients in India has not been reported. Aim: Anti-IgE antibody had been used in severe persistent allergic asthma in adults. Here we are presentating our experience of 30 patients with 52 weeks of Anti IgE Therapy follow-up. Method and Materials: 30 (16 male and 14 female) patients, with mean age of 49 having severe persistent allergic asthma with recurrent exacerbations and having oral/ IV/ high dose ICS (Inhaled Corticosteroids) who received Omalizumab 300mg once a month for 6 month to 1 year were included in the study. Total dose of oral Steroids, use of rescue medications, changes in lung function ( FEV1) and ICS dose were recorded at the baseline, 16 weeks and at 52 weeks. Results: There was significant reduction in use of oral steroid at 16 week and 52 weeks -10.5mg and 22.5mg respectively . Use of rescue medications decreased by -7.90 puffs (p<0.001) at 16 weeks and by -13.67 puffs (p -<0.001) at 52 weeks. Improvements in lung Function ( FEV1) observed was 700 ml from Base Line after 52 weeks therapy. ACT Score showed significant improvement at 16 wks and at 52 wks. Conclusion: Use of anti-IgE antibody for 1 year led to significant improvement in patients with severe persistent allergic asthma.

Follow up of Patients With Severe Allergic Asthma on one year Anti-IgE (Omalizumab) Therapy